| First Author | Ortega-Molina A | Year | 2021 |
| Journal | Cell Rep | Volume | 36 |
| Issue | 2 | Pages | 109372 |
| PubMed ID | 34260908 | Mgi Jnum | J:320567 |
| Mgi Id | MGI:6874567 | Doi | 10.1016/j.celrep.2021.109372 |
| Citation | Ortega-Molina A, et al. (2021) Inhibition of Rag GTPase signaling in mice suppresses B cell responses and lymphomagenesis with minimal detrimental trade-offs. Cell Rep 36(2):109372 |
| abstractText | B lymphocytes are exquisitely sensitive to fluctuations in nutrient signaling by the Rag GTPases, and 15% of follicular lymphomas (FLs) harbor activating mutations in RRAGC. Hence, a potential therapeutic approach against malignant B cells is to inhibit Rag GTPase signaling, but because such inhibitors are still to be developed, efficacy and safety remain unknown. We generated knockin mice expressing a hypomorphic variant of RagC (Q119L); RagC(Q119L/+) mice are viable and show attenuated nutrient signaling. B lymphocyte activation is cell-intrinsically impaired in RagC(Q119L/+) mice, which also show significant suppression of genetically induced lymphomagenesis and autoimmunity. Surprisingly, no overt systemic trade-offs or phenotypic alterations caused by partial suppression of nutrient signaling are seen in other organs, and RagC(Q119L/+) mice show normal longevity and normal age-dependent health decline. These results support the efficacy and safety of moderate inhibition of nutrient signaling against pathological B cells. |
